A Look Back, A Look Forward Messages From the Past and Current Presidents of the European Society of Cardiology by Vardas, Panos E. & Pinto, Fausto J.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 5 , N O . 7 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 4 . 1 2 . 0 2 9GUEST EDITOR’S PAGEFrom the *Department of Cardiology, University of Crete
Greece; and the yCardiology Department, University Hos
Hospitalar Lisboa Norte, Lisbon, Portugal.A Look Back,
A Look Forward
Messages From the Past and
Current Presidents of the
European Society of Cardiology
Panos E. Vardas, MD, PHD,* Immediate Past President,
European Society of Cardiology
Fausto J. Pinto, MD, PHD,y President, European Society of CardiologyMY EUROPEAN SOCIETY OF CARDIOLOGY
PRESIDENCY, 2012 TO 2014: LEADING THE
LARGE, COMPLEX, INNOVATIVE, AND
HETEROGENEOUS
Panos E. Vardas, MD, PhD
Management and leadership are not synonymous,
although they often considerably overlap when the
operational plans of companies, institutes, or profes-
sional associations require effective solutions. Man-
agers cope with the detailed complexities, whereas
leaders struggle for change, as mentioned in the
management classics.
By the time I was elected as president of the Eu-
ropean Society of Cardiology (ESC), at the age of 60
years, I had already ﬁnished my 4-year term as dean
of the Medical School at the University of Crete,
ﬁnished my 2-year mandate as president of the Hel-
lenic Society of Cardiology, and was halfway through
my mandate as president of the European Heart
Rhythm Association, a pivotal pillar of the ESC. These
interesting and varied experiences had provided an
in-depth understanding of the opportunities and
challenges that a president of a nonproﬁt scientiﬁc
society would face, either as a manager or leader,
during this 2-year mandate.
It was, therefore, clear that my primary goals were
to successfully advance existing projects and to deal
methodically and patiently with crises at different, Heraklion,
pital, Centrolevels, while simultaneously implementing change
during my rather short tenure. Based on past expe-
riences, I was convinced that the changes that I
wished to accomplish should be recommended and
put into motion as soon as possible, even in the ﬁrst
months of my presidency.
In my speech at the 2012 general assembly,
immediately after assuming the ESC presidency, I
focused on my main strategic choices for the next 2
years. Seizing this opportunity, I underlined the need
for unity among the heterogeneous groups that our
society comprises, as well as the need to safeguard
our leading successful projects, such as our annual
congress, publications, guidelines, and registries, to
name but a few. In parallel, I stressed the need for
speciﬁc, feasible, and achievable changes that would
provide the Society with the opportunity to claim its
role over the coming 15 years.
It took me, as well as the chief executive ofﬁcer of
the ESC, a great deal of effort to carefully evaluate the
parameters that would facilitate work on our highly
visible and acknowledged projects despite the unfa-
vorable economic environment, especially in the ﬁeld
of cardiovascular medicine.
Needless to say, the new regulatory environment
and subsequent signiﬁcant changes dominated our
daily discussions. Envisioning the future needs of our
society and our profession, I asked the board for the
immediate expansion of the ESC to add new ofﬁces in
Brussels, in addition to the central headquarters in
Nice, France.
I was fortunate enough that convincing our board
of the strategic signiﬁcance of this proposal did not
take valuable time in endless debate. Instead, all of
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trustful allies in this ambitious venture, which is
already in its ﬁrst year of operation in the political
capital of Europe.
For all of us—the senior volunteers of the Society—
the creation of something that had widespread accep-
tance may well be the most substantial incentive. The
new basis of our Society in Brussels has been the
driving force for the development of our innovative
strategic project, the European Heart Agency: a
complex structure designed to serve the needs of
health care policy, research, and a speciﬁc educational
initiative, with the ofﬁcial cooperation of our Society
along with the support of selected universities.
Apart from trying to upgrade our political presence
and visibility as a signiﬁcant player in cardiovascular
science, we aimed to develop important collabora-
tions that would promote our institutional character
for the good of the patients, our Society members,
and even beyond, our profession as a whole.
At this point, I would like to brieﬂy express my
reﬂections on the present and future of large medical
scientiﬁc societies. In the last 50 years, large societies
have contributed tremendously to the development
of medical science as a whole and that of cardiovas-
cular medicine speciﬁcally. They have succeeded not
only in bringing together specialists, but also in
advancing systematic continuing medical education
and promoting evidence-based medicine.
However, as the president of a society as large as the
ESC, it is easy for me to recognize that rapid develop-
ment in medicine, medical technologies, and health
systemmanagement presupposes amoremodern legal
entity that would undertake measures and initiatives
in areas beyond traditional diagnostic and therapeutic
medicine—such as health care quality, standardi-
zation, health economics, and health technology
assessment—and would have a much deeper under-
standing of issues related to regulations of both phar-
maceutical therapies andmedical device technologies.
The cataclysmic advancements in digital health will
force existing societies to review their strategic plans
and adapt them to today’s rapidly changing world, or
large societies will suffer the fate of the dinosaurs.
Indeed, I strongly believe that the leaders of large
scientiﬁc societies stand at a crossroads, as they
need to make important decisions that seriously
consider the main drivers of the forthcoming decades
in medicine. The empowered patient, the prevailing
private insurance realities, the unbearable health care
cost for the traditional social welfare state, and as I
mentioned previously, the rapid developments in
digital health care and education should be high on
the agenda of the prominent medical associations.As my 2-year mandate ended in September 2014, I
felt satisﬁed that a signiﬁcant number of colleagues,
those who were members of our board as well as the
National Cardiac Societies and ESC associations,
councils, and working groups, stood by my efforts
and supported my ideas for substantial changes in our
strategic plan and our statute.
Personally, these 2 years were very important in
my long academic route, and I was delighted to
celebrate this endeavor together with 30,000 friends,
colleagues, companions, and specialists in cardio-
vascular medicine in fabulous Barcelona. I would like
to thank all of them: those who chose me to be
president, those who supported me and believed in
me, those who worked with me, and, surely, those
who patiently waited for me at home.
CARDIOVASCULAR MEDICINE AT A
CROSSROADS: HOW SCIENTIFIC SOCIETIES
CAN HELP SHAPE THE FUTURE
Fausto J. Pinto, MD, PhD
Cardiovascular diseases remain the main cause of
mortality and morbidity worldwide despite all of the
medical developments that have reduced the mor-
tality rate of these conditions. Surprisingly or not,
this simple fact is still unknown to the majority of the
lay population, although it has been conﬁrmed by all
international bodies that monitor health status
worldwide. In recent surveys of the populations of
varied countries, 80% replied that cancer is the
number 1 cause of death.
The second challenge facing cardiovascular dis-
eases is that cardiology has quickly become a high-
tech specialty, increasing the need for strong
involvement of the technology industry, either
through medical devices or pharmaceutical agents.
There is also the perception and potential reality that
ﬁnancial investment in cardiovascular research has
stagnated, if not decreased. This is mostly because
the development of new drugs and the organization
of new trials requires large “mega trials,” which are
too expensive and increasingly difﬁcult to organize.
The whole issue of surrogates and the matrix of
clinical trials is currently being discussed.
In this setting, the role of scientiﬁc medical soci-
eties has been continuously challenged, and the
medical community should review and discuss how
to make the best use of these societies. The most
efﬁcient strategies need to be clearly deﬁned,
particularly in the current global atmosphere. This
necessitates determined leaders with imagination
and passion, striving for excellence and willing to
make a difference in a responsible way.
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main providers of continuous medical education, while
they simultaneously develop tools to promote improved
patient management. The Royal Society of London,
created in 1660, was 1 of the oldest medical societies.
However, their role has been progressivelymore relevant,
particularly after the Second World War. This is the case
for the ESC, which was formally founded in 1950 by rep-
resentatives of 14 national societies (Belgium, Denmark,
Finland, France, Greece, Italy, the Netherlands, Norway,
Portugal, Spain, Sweden, Switzerland, United Kingdom,
and Yugoslavia). Since that time, the Society has grown
immensely, and is now a federation of 56 national soci-
eties, 39 afﬁliated societies, 6 associations, 15 working
groups, and 5 councils. From a small organization, it has
grown to become the largest cardiovascular society in the
world, representing approximately 90,000 health pro-
fessionals, with headquarters in Nice, France, and, since
February 2013, the formation of a delegation in Brussels.
Although the needs are vast, medical societies
should tailor their efforts into several concentrated
areas. In Europe, it is my strong belief that we need to
strengthen 2 major areas: a very strong educational
component and a visible and strong advocacy policy.
(This does not mean that all other areas should be
disregarded.) However, we must keep in mind that a
scientiﬁc society is made of people who have a lot of
differences for several reasons but have a common
goal: to ﬁght disease (in our case, cardiovascular dis-
ease), whether as a clinician/health professional tak-
ing care of patients, or as a scientist trying to expand
and improve our understanding of the different
mechanisms underlying the different disease pro-
cesses or developing new interventional strategies.
Values should be preserved in a scientiﬁc society
as in many other areas of human activities. Our
values can be summarized as the 6 Cs: Continuity,
Consolidation, Consistency, Constructive, Creativity,
Charisma.
Thus, it is essential to establish well-crafted, long-
term strategic plans that take into account the re-
alities of the moment and have the ability to foresee
the challenges of the future.
The main pillars that can be envisaged as the core
ESC strategic goals in the future can be summarized
in the main categories including: Membership,
Education, Guidelines and standards, Research and
training, and Advocacy and lobbying.
MEMBERSHIP. At the ESC, our constituent bodies are
the backbone of the Society. All major decisions need
to be clearly discussed and shared with our constit-
uent bodies in a very open and transparent way. The
fair involvement of all of them in the different ac-
tivities of the Society is necessary to maintain ourfamily as a unit. Also, our speciﬁcities and differences
need to be wisely and properly addressed.
The whole membership concept needs to evolve
and adapt to the fast-moving changes in our society.
As examples, the current situation in Europe (and
beyond) regarding industry support or the change in
regulations that several countries are adopting will
obviously have an effect. All changes need to account
for the different expectations and goals of the varied
constituent bodies.
It is also important to stress the importance of our
afﬁliate societies and members outside of the ESC
family. Thus, the creation of an International Affairs
Department with the goal of turning ESC was crucial
as the main reference for global education, guide-
lines, and registries. This implies a close collaboration
with afﬁliate societies to increase ESC’s outreach and
inﬂuence.
The associations were an essential and wise devel-
opment under Jean-Pierre Bassand’s presidency in
2003. They allowed the cardiology world to be under 1
ceiling, keeping the unity of the cardiology community
in Europe. This is what some call the “European
Miracle.” The experience has shown that autonomy—
when responsibly exercised within a larger structure—
can be beneﬁcial for the whole community.
Another successful initiative was the creation of
the Cardiologists of Tomorrow, started a few years
ago, which guarantees the future of our society. The
involvement of the younger generations in the ac-
tivities of the Society is of crucial importance in
bringing “new blood” and brain power, which are
always a source of dynamism and novelty.
EDUCATION. The ESC has the responsibility of being
1 of the main education providers in cardiovascular
medicine. Our education efforts should be focused on
innovation and diversity to adapt to the modern
technologies and concepts in medical education.
The integrated e-learning platform (ESCeL),
developed over the last few years, represents a very
powerful tool with multiple potential uses at
different levels, with an endless capacity to include
different content, and with the possibility to be used
by the different constituent bodies.
Congresses are traditional tools used by scientiﬁc
societies to disseminate knowledge, to educate the
community, and as a platform for networking. The ESC
is currently organizing the largest congress in cardio-
vascular medicine in the world, withmore than 30,000
participants, which is a source of joy and pride. How-
ever, the classical model of a big congress is at risk in
the current environment of regulatory changes and
economic crisis. Therefore, preventive measures need
to be developed considering the most likely scenarios
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need to innovate on the congress model, such as to
make it a yearlong product (e.g., Congress 365) or to
organize virtual congresses. This is a problem that
involves all medical societies and is a good example of
how cooperation in ﬁnding solutions could be impor-
tant. With contemporary technology and within the
new environment, it seems to be crucial to prepare
good Distance Learning Programs with regular facili-
tation, for instance, of webinars and courses.
Education links with certiﬁcation and accreditation
will be key elements in the near future. We need to be
ready for these changes and to continue to be the
educational providers of the program. This will not
only increase the visibility and credibility of ESC, but
could also provide a source of revenue. The provision
of multiple-choice questions to the different users
and of credits toward continuing medical education is
1 example.
GUIDELINES AND STANDARDS. Producing guide-
lines for management of different clinical conditions
has become one of the most visible activities of scien-
tiﬁc societies, with a major effect on medical practice.
The ESC has been producing 4 to 5 new (or revised)
guidelines yearly, which are widely respected and
quoted. A good program of guideline dissemination
and implementation is essential for the promotion of
these guidelines, and different mechanisms and tools
can be used to achieve this, including an extensive use
of the online portal and the linkwith national societies.
It is only possible to promote guidelines if they will be
adopted by each country and the local community.
This has been achieved in Europe, because the ESC
guidelines have been endorsed by all member coun-
tries. In many cases, they are translated into the local
language, and many activities are organized by the
local societies, with the support of the ESC, for its
dissemination and implementation.
Medical societies also have the responsibility to
develop standards not only of best medical practice
but also of hospitals, departments, and laboratories.
RESEARCH AND TRAINING. The role of scientiﬁc
societies to promote biomedical research is be-
coming increasingly prevalent, particularly during
the current era when the political and ﬁnancial situ-
ations across Europe (and the world) are facingunprecedented challenges. We can achieve success
through different ways, including awarding training
and research grants, supporting research programs, or
developing our own programs, including observa-
tional research such as registries. The Euro Observa-
tional Research Program was created to collect data
that will show how cardiovascular medicine is being
practiced across Europe.
ADVOCACY AND LOBBYING. Scientiﬁc societies have
to become more involved with advocacy issues. It is
also a duty of the scientiﬁc and medical community to
closely cooperate with decision makers to support the
best possible political decisions. This has been a long-
standing commitment of the ESC over the last few
years, and was further reinforced by the opening of a
delegation in Brussels named the European Heart
Agency. This has provided a strong tool for the ESC to
develop and implement different activities that will
achieve our strategic goals. As an example, the ESC
shouldwork togetherwith different entities—including
other professional societies, the European Commis-
sion, the different directorates, European Parliament,
European Research Council, and patient organizations,
to name a few—to be seen as an advocate for patients
and cardiovascular health care professionals.
Scientiﬁc societies have an increased responsibility
to help shape the future of health care. This should also
include closer cooperation between the larger organi-
zations, including the ESC, the American College of
Cardiology, and the American Heart Association. In
addition, global organizations, such as theWorld Heart
Federation, could play a signiﬁcant role in addressing
universal issues, such as advocacy and prevention,
supported by strong cross-continental organizations.
I will conclude by quoting Goethe in what I believe
should be the leitmotif, or guiding motif, of a scien-
tiﬁc society: “Knowing is not enough; we must apply.
Willing is not enough; we must do” (1).
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